Trump signs order to fast-track psychedelic research, including ibogaine
TL;DR
President Trump signed an executive order to ease federal restrictions on psychedelic research, including ibogaine, with a $50 million funding commitment and a pathway for ibogaine to be studied and used under the FDA's Right To Try for seriously ill patients. The FDA will also add three psychedelics to the National Priority Voucher program to accelerate reviews, while maintaining oversight and not legalizing the drugs. The move aims to spur new mental-health treatments but underscores safety concerns and the need for more robust clinical trials.
- Trump signs executive order to research psychedelics, including ibogaine, for mental health treatment CBS News
- Trump is savaging allies who criticize the Iran war. But he’s treating Joe Rogan very differently CNN
- Trump signs executive order on psychedelic drugs — with Joe Rogan by his side MS NOW
- Trump signs order fast tracking review of psychedelics for mental health disorders NPR
- Trump signs order to speed review of psychedelics, including the controversial drug ibogaine Los Angeles Times
Want the full story? Read the original reporting
Read on CBS News